JPH11504036A - ケモカイン結合タンパク質およびその使用 - Google Patents
ケモカイン結合タンパク質およびその使用Info
- Publication number
- JPH11504036A JPH11504036A JP8532329A JP53232996A JPH11504036A JP H11504036 A JPH11504036 A JP H11504036A JP 8532329 A JP8532329 A JP 8532329A JP 53232996 A JP53232996 A JP 53232996A JP H11504036 A JPH11504036 A JP H11504036A
- Authority
- JP
- Japan
- Prior art keywords
- cbp
- protein
- myxoma
- chemokine
- mip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.被験者の免疫病理学的疾患を治療する方法であって、 約30〜40kDの分子量を有し; 粘液腫T7インターフェロンγ受容体相同体と相同のアミノ酸配列を有し;か つ、 粘液腫T7インターフェロンγ受容体相同体の生物学的機能を有する ことを特徴とする抗炎症タンパク質の治療学的に有効な量を被験者に投与するこ とを含む方法。 2.抗炎症タンパク質がケモカイン結合性タンパク質である、請求項1に記載の 方法。 3.ケモカインがクラスα又はクラスβケモカインである、請求項2に記載の方 法。 4.ケモカインがCTAP−III、gro/MGSA、ENA-78、MCP-1、インタ ーロイキン-8、RANTES、MIP-1α、及びMIP-1βからなる群から選ば れる、請求項3に記載の方法。 5.免疫病理学的疾患が微生物感染、悪性疾患及び転移、喘息、冠状動脈再狭窄 、自己免疫疾患、肝硬変、内毒素血症、アテローム硬化症、並びに再灌流障害か らなる群から選ばれる、請求項1に記載の方法。 6.請求項1に記載の方法であって、さらに被験者に抗生物質又は抗ウイルス薬 を投与することを含む方法。 7.抗炎症タンパク質の投与が1投与当たり約10pg〜 100μg の用量である、請 求項1に記載の方法。 8.抗炎症タンパク質の投与が皮下投与、静脈内投与、動脈内投与、筋肉内投与 、直腸内投与及び経皮投与からなる群から選ばれる、請求項1に記載の方法。 9.約30〜40kDの分子量を有し;粘液腫T7インターフェロンγ受容体相同体と 相同のアミノ酸を有し;かつ粘液腫T7インターフェロンγ受容体相同体の生物 学的機能を有する、免疫治療学的に有効な量の抗炎症タンパク質の少なくとも1 つを薬理学的担体中に含む医薬組成物。 10.抗炎症タンパク質がI型ケモカイン結合性タンパク質である、請求項9に記 載の組成物。 11.ケモカインがクラスα又はクラスβケモカインである、請求項10に記載の組 成物。 12.ケモカインがCTAP−III、gro/MGSA、ENA-78、MCP-1、インタ ーロイキン-8、RANTES、MIP-1α、及びMIP-1βからなる群から選ば れる、請求項11に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42485095A | 1995-04-19 | 1995-04-19 | |
US08/424,850 | 1995-04-19 | ||
PCT/IB1996/000680 WO1996033730A2 (en) | 1995-04-19 | 1996-04-19 | Chemokine binding protein and methods of use therefor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007181221A Division JP2007332145A (ja) | 1995-04-19 | 2007-07-10 | ケモカイン結合タンパク質およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11504036A true JPH11504036A (ja) | 1999-04-06 |
JP4077876B2 JP4077876B2 (ja) | 2008-04-23 |
Family
ID=23684134
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53232996A Expired - Fee Related JP4077876B2 (ja) | 1995-04-19 | 1996-04-19 | ケモカイン結合タンパク質およびその使用 |
JP2007181221A Ceased JP2007332145A (ja) | 1995-04-19 | 2007-07-10 | ケモカイン結合タンパク質およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007181221A Ceased JP2007332145A (ja) | 1995-04-19 | 2007-07-10 | ケモカイン結合タンパク質およびその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5834419A (ja) |
EP (1) | EP0840615B1 (ja) |
JP (2) | JP4077876B2 (ja) |
AT (1) | ATE243526T1 (ja) |
AU (1) | AU718049B2 (ja) |
CA (1) | CA2218499C (ja) |
DE (1) | DE69628838T2 (ja) |
DK (1) | DK0840615T3 (ja) |
ES (1) | ES2202452T3 (ja) |
PT (1) | PT840615E (ja) |
WO (1) | WO1996033730A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039644A1 (ja) * | 2003-10-23 | 2005-05-06 | Kurume University | 可溶型インターフェロンγ受容体遺伝子導入法および動脈硬化予防または治療用組成物 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495515B1 (en) * | 1995-04-19 | 2002-12-17 | Viron Therapeutics, Inc. | Chemokine binding protein and methods of use therefor |
EP1034789A1 (en) * | 1996-05-22 | 2000-09-13 | University Of Alberta | Type-2 chemokine binding proteins and methods of use therefor |
IL127166A0 (en) * | 1996-05-22 | 1999-09-22 | Univ Alberta | Type-2 chemokine binding proteins and methods of use therefor |
ATE323170T1 (de) | 1997-02-21 | 2006-04-15 | Oxxon Therapeutics Ltd | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
AU2218999A (en) * | 1998-01-09 | 1999-07-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Broad spectrum chemokine antagonist and uses thereof |
US6869606B1 (en) | 1999-02-22 | 2005-03-22 | Millennium Pharmaceuticals, Inc. | Biotinylated-chemokine antibody complexes |
US6589933B1 (en) | 1999-04-02 | 2003-07-08 | Viron Therapeutics, Inc. | Myxoma chemokine binding protein |
WO2001004318A2 (en) * | 1999-07-12 | 2001-01-18 | Viron Therapeutics, Inc. | Myxoma virus genes for immune modulation |
AU2001261738A1 (en) * | 2000-05-17 | 2001-11-26 | London Health Sciences Centre | Compositions and methods for promoting immunosuppression |
US6894155B2 (en) | 2000-10-11 | 2005-05-17 | Viron Therapeutics | Nucleic acid molecules and polypeptides for immune modulation |
CA2428097A1 (en) | 2000-12-04 | 2002-06-13 | Viron Therapeutics, Inc. | Immunomodulatory protein derived from the yaba monkey tumor virus |
US7718368B2 (en) | 2000-12-04 | 2010-05-18 | Viron Therapeutics Inc. | Immunomodulatory protein and useful embodiments thereof |
US20040241163A1 (en) * | 2001-04-05 | 2004-12-02 | Thomas Shenk | Compositions and methods for treating inflammation and related conditions |
US20020165161A1 (en) * | 2001-05-04 | 2002-11-07 | Surromed, Inc. | Chemokine-binding proteins for treating congestive heart failure |
AU2002368225A1 (en) * | 2001-10-10 | 2004-05-04 | Mount Sinai School Of Medicine Of The City University Of New York | Viral interferon antagonists and uses therefor |
US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
US20030161937A1 (en) * | 2002-02-25 | 2003-08-28 | Leiby Mark W. | Process for coating three-dimensional substrates with thin organic films and products |
WO2003092615A2 (en) * | 2002-05-01 | 2003-11-13 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
EP1572736A2 (en) * | 2002-12-10 | 2005-09-14 | Endocube SAS | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
AU2006204133A1 (en) * | 2005-01-04 | 2006-07-13 | University Of Rochester | Blockade of ELR+CXC chemokines as a treatment for inflammatory and autoimmune disease |
EP2185719B1 (en) * | 2007-08-02 | 2013-11-13 | NovImmune SA | Anti-rantes antibodies and methods of use thereof |
US8251876B2 (en) | 2008-04-22 | 2012-08-28 | Hill-Rom Services, Inc. | Breathing exercise apparatus |
US9180271B2 (en) | 2012-03-05 | 2015-11-10 | Hill-Rom Services Pte. Ltd. | Respiratory therapy device having standard and oscillatory PEP with nebulizer |
US20140130373A1 (en) | 2012-11-15 | 2014-05-15 | Nike, Inc. | Article Of Footwear Incorporating A Knitted Component |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464938A (en) * | 1990-04-09 | 1995-11-07 | Immunex Corporation | Isolated viral protein TNF antagonists |
WO1991016431A1 (en) * | 1990-04-24 | 1991-10-31 | Schering Corporation | Soluble, truncated gamma-interferon receptors |
-
1996
- 1996-04-19 WO PCT/IB1996/000680 patent/WO1996033730A2/en active IP Right Grant
- 1996-04-19 CA CA002218499A patent/CA2218499C/en not_active Expired - Fee Related
- 1996-04-19 DE DE69628838T patent/DE69628838T2/de not_active Expired - Lifetime
- 1996-04-19 AU AU62379/96A patent/AU718049B2/en not_active Ceased
- 1996-04-19 ES ES96921023T patent/ES2202452T3/es not_active Expired - Lifetime
- 1996-04-19 AT AT96921023T patent/ATE243526T1/de not_active IP Right Cessation
- 1996-04-19 EP EP96921023A patent/EP0840615B1/en not_active Expired - Lifetime
- 1996-04-19 US US08/634,924 patent/US5834419A/en not_active Expired - Lifetime
- 1996-04-19 PT PT96921023T patent/PT840615E/pt unknown
- 1996-04-19 JP JP53232996A patent/JP4077876B2/ja not_active Expired - Fee Related
- 1996-04-19 DK DK96921023T patent/DK0840615T3/da active
-
2007
- 2007-07-10 JP JP2007181221A patent/JP2007332145A/ja not_active Ceased
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039644A1 (ja) * | 2003-10-23 | 2005-05-06 | Kurume University | 可溶型インターフェロンγ受容体遺伝子導入法および動脈硬化予防または治療用組成物 |
Also Published As
Publication number | Publication date |
---|---|
US5834419A (en) | 1998-11-10 |
WO1996033730A3 (en) | 1996-12-12 |
DE69628838T2 (de) | 2004-05-06 |
EP0840615A2 (en) | 1998-05-13 |
PT840615E (pt) | 2003-10-31 |
DK0840615T3 (da) | 2003-08-18 |
JP2007332145A (ja) | 2007-12-27 |
CA2218499C (en) | 2007-02-20 |
AU6237996A (en) | 1996-11-18 |
WO1996033730A2 (en) | 1996-10-31 |
CA2218499A1 (en) | 1996-10-31 |
EP0840615B1 (en) | 2003-06-25 |
ES2202452T3 (es) | 2004-04-01 |
DE69628838D1 (de) | 2003-07-31 |
JP4077876B2 (ja) | 2008-04-23 |
ATE243526T1 (de) | 2003-07-15 |
AU718049B2 (en) | 2000-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11504036A (ja) | ケモカイン結合タンパク質およびその使用 | |
Hile et al. | The influence of interferon on healthy and diseased skin | |
JP4191255B2 (ja) | ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 | |
JPH09510620A (ja) | 神経膠細胞神経栄養因子(gdnf)をコードする組み換えアデノウィルス | |
EP0901379B1 (en) | Type-2 chemokine binding proteins and methods of use therefor | |
JP2003047492A (ja) | ヒトケモカインベータ−9 | |
US6495515B1 (en) | Chemokine binding protein and methods of use therefor | |
CA2098926A1 (en) | Medicaments for the treatment of papillomavirus diseases | |
US7638481B2 (en) | Treatment of spinal cord injury | |
US10548946B2 (en) | Therapeutic compositions for neutralizing type I interferons, and methods of use | |
ZA200302315B (en) | Chemokine mutants in the treatment of multiple sclerosis. | |
US6589933B1 (en) | Myxoma chemokine binding protein | |
WO2020108427A1 (zh) | 一种新型干扰素α及其制备方法、组合物和用途 | |
EP1034789A1 (en) | Type-2 chemokine binding proteins and methods of use therefor | |
CN109467597B (zh) | 一种新型干扰素及其制备方法、组合物和用途 | |
AU754225B2 (en) | Chemokine binding protein and methods of use therefor | |
CN111303253A (zh) | 一种草鱼Fibulin4蛋白结合多肽及其在抗病毒中的应用 | |
MXPA98009733A (en) | Chlorine type 2 ligature proteins and methods for your | |
CN111450232B (zh) | 一种融合蛋白在制备治疗丙型肝炎药物中的应用 | |
AU2814801A (en) | Type-2 chemokine binding proteins and methods of use therefor | |
US20040241163A1 (en) | Compositions and methods for treating inflammation and related conditions | |
KR20010092029A (ko) | 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법 | |
JPH06247873A (ja) | 肝実質細胞増殖因子の誘導剤 | |
WO2020108428A1 (zh) | 重组人抗病毒细胞因子及其制备方法、组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061026 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070611 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080108 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080204 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110208 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |